Notice of Annual General Meeting

Solvonis Therapeutics PLC

27 May 2026

 

27 May 2026

Solvonis Therapeutics plc

("Solvonis" or the "Company")

Notice of Annual General Meeting (the "AGM")

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, is pleased to announce that the notice of the Company's 2026 AGM and proxy form have today been posted to shareholders and can be found on the Company's website at https://solvonis.com/investor-relations/shareholder-circulars.

The Annual General Meeting will take place at 9.00am on 19 June 2026 at the Company's registered office being, 25 Eccleston Place, London SW1W 9NF.

In compliance with Listing Rule 9.6.1R, the notice of AGM and proxy form have today been submitted to the National Storage Mechanism and will shortly be available at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Enquiries:

Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
[e-mail]

Singer Capital Markets (Broker)
Phil Davies
[phone]

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and discovery-stage compounds across addiction and psychiatry.

The Company's lead programmes target Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with additional development and discovery work supporting expansion into further addiction and psychiatric indications, including stimulant use disorder and depressive disorders.

 Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for a Phase 2b trial in the United States targeting moderate-to-severe AUD. The Company's PTSD discovery programme has identified SVN-114 as a lead compound, emerging from a proprietary compound series designed to modulate key brain signalling systems associated with emotional processing and social behaviour.

In parallel, Solvonis is advancing proprietary CNS discovery programmes supported by a dedicated compound library to identify new small-molecule modulators of key neurotransmitter systems. This platform enables efficient early-stage innovation and supports the Company's integrated approach to developing therapies across addiction and psychiatry.

With a capital-efficient development model and a focus on partnering opportunities, Solvonis aims to deliver sustained value through innovation in CNS therapeutics.

solvonis.com | LinkedIn | X (Twitter)

 

END